RECURSION PHARMACEUTICALS, INC. ·
RXRX 8-K 2026-09-21
RECURSION PHARMACEUTICALS, INC. (RXRX) 8-K dated 2026-09-21 — accession 0001601830-26-000112.
RECURSION PHARMACEUTICALS, INC. (RXRX) is a biotechnology company listed on NASDAQ.
RECURSION PHARMACEUTICALS, INC. filed a 8-K on 2026-09-21. Accession 0001601830-26-000112.
This 8-K covers: Material agreement (Item 1.01). SEC EDGAR holds the official filing and its exhibits.
Latest reported RXRX revenue for 2025-12-31 was $74.7M. Net income was -$644.8M. Revenue was up 26.9% from 2024-12-31 to 2025-12-31. RXRX currently screens at market cap $1.75B.
Not investment advice. The RXRX SEC hub lists recent forms. The stock page is the research view.